Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat fibrotic diseases. Fibrosis is a process that occurs in many diseases, when normal healthy tissue is replaced with scar tissue, compromising normal function and leading ultimately to organ failure. Promedior's proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that acts through a unique mechanism to activate a regulatory switch upstream in the fibrosis cascade.
Promedior has built a strong team experienced in developing, advancing, and commercializing products for a wide range of disorders including orphan diseases. The company has successfully advanced its lead therapeutic candidate through Phase 1 human clinical trials. Promedior has raised over $65 million from leading global healthcare venture investors and secured important intellectual property relating to the pioneering discoveries and applications of the company's therapeutics.
Proprietary platform: Promedior's drug candidates are based on Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. Normal wound healing involves the inflammation, proliferation, and resolution pathways. Fibrosis occurs when the normal wound healing response gets locked into the proliferation pathway, resulting in scar tissue and, ultimately, organ dysfunction.
Pentraxin-2 is a naturally occurring protein that causes the immune system to simultaneously turn off proliferation and turn on the resolution pathway, specifically in areas of tissue injury. Other therapeutic approaches in development typically focus on inhibiting single targets downstream in the fibrosis cascade, many of which are redundant. Pentraxin-2 works as an upstream agonist, potentially halting further progression of fibrotic disease and promoting beneficial healing.
Clinical advancements: Promedior has successfully advanced its lead therapeutic candidate in human clinical trials. The company's lead product, PRM-151, has recently completed a Phase 1b clinical study in idiopathic pulmonary fibrosis (IPF) patients, and these data will be presented at a medical meeting in May, 2013. In an earlier Phase 1a study, PRM-151 was generally safe and well tolerated. Additionally, PRM-151 demonstrated robust efficacy in multiple preclinical models of fibrotic disease, including reductions in established fibrosis.
Strategic focus: Promedior is initially focused on rare fibrotic diseases, such as IPF and myelofibrosis, and retinal fibrovascular diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR). To maximize the potential of its drug candidates to address the unmet needs of patients, the Company is exploring corporate partnerships in some larger market indications for fibrosis-related diseases.
Crystal structure of human Pentraxin-2, a naturally occurring protein that is the foundation of Promedior's proprietary platform. Learn More >
Based on the broad potential of its Pentraxin-2 platform, Promedior is developing a pipeline of potential therapies. Learn More >